Pfizer Inc. received US clearance for a vaccine that protects infants from RSV by immunizing their pregnant mothers, positioning the drugmaker to enter a competitive new market for the common but dangerous virus in young children.
The Food and Drug Administration gave the green light for Pfizer’s Abrysvo ahead of the RSV season, according to a statement. The Centers for Disease Control and Prevention must still determine how Pfizer’s shot will be used.
Pfizer shares rose less than 1% in extended trading in New York.
It’s taken 60 years for scientists to develop protection against RSV. After a series ...
